Table 2.
The treatment and efficacy of CNSL patients received CD19/22 CAR T-cells infusion following ASCT.
| Case | Conditioning regimen | CD34+ cells (*106/kg) | CD22 CAR T-cells (*106/kg) | CD19 CAR T-cells (*106/kg) | Neutrophil engraftment (d) | CRS grade/symptoms | ICANS grade/symptoms | Best response (duration: months) | Survivala |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Dox + BEAM | 2.0 | 3.7 | 4.4 | 12 | 1 (Fever) | N | CR (24.17) | Yes |
| 2 | TBC | 32.4 | 4.0 | 4.0 | 13 | N | N | CR (19.27) | Yes |
| 3 | Dox + BEAM | 16.4 | 4.1 | 6.0 | 9 | 1 (Fever) | N | CR (18.53) | Yes |
| 4 | TBC | 13.1 | 4.0 | 4.0 | 9 | 2 (Fever; Hypotension) | N | CR (17.43) | Yes |
| 5 | Dox + BEAM | 8.1 | 8.4 | 9.2 | 20 | 1 (Fever) | N | CR (16.03) | Yes |
| 6 | Dox + BEAM | 2.9 | 4.3 | 3.6 | 19 | 1 (Fever) | N | CR (14.03) | Yes |
| 7 | TBC | 8.4 | 2.6 | 2.0 | 12 | 1 (Fever) | 1 (Apathetic; Memory impairment) | PD (0.40) | No |
| 8 | TBC | 33.4 | 5.0 | 5.0 | 11 | 1 (Fever) | N | PD (0.60) | No |
| 9 | Dox + BEAM | 3.2 | 2.7 | 4.3 | 15 | 1 (Fever) | N | CR (11.17) | Yes |
| 10 | TBCF | 5.7 | 5.0 | 5.0 | 15 | 1 (Fever) | 3 (Delirious; Disoriented) | CR (4.67) | Yes |
| 11 | TBCF | 8.6 | 5.8 | 2.0 | 13 | 2 (Fever; Hypoxemia) | N | PR (0.90) | Yes |
| 12 | TBC | 4.0 | 2.8 | 2.0 | 17 | N | 1 (Lethargy) | PR (0.33) | Yes |
| 13 | TBC | 19.3 | 5.0 | 5.0 | 12 | 1 (Fever) | N | PR (0.23) | Yes |
TBC ± F thiotepa, busulfan, cyclophosphamide ± Flu, BEAM carmustine, etoposide, cytarabine, melphalan, CAR chimeric antigen receptor, Neu neutrophil, CRS cytokine-release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome.
aFollow-up to March 15, 2021 or death.